Silence Therapeutics Management
Management criteria checks 1/4
Silence Therapeutics' CEO is Craig Tooman, appointed in Feb 2022, has a tenure of 2.25 years. total yearly compensation is £7.30M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $244.40K. The average tenure of the management team and the board of directors is 1.7 years and 4.3 years respectively.
Key information
Craig Tooman
Chief executive officer
UK£7.3m
Total compensation
| CEO salary percentage | 6.5% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 1.7yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Feb 07
Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Nov 27Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
Sep 08Silence Therapeutics prices 5.95M ADSs at $9.50/share
Aug 12New finance chief for Silence Therapeutics
Jan 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | UK£7m | UK£473k | -UK£43m |
| Sep 30 2023 | n/a | n/a | -UK£43m |
| Jun 30 2023 | n/a | n/a | -UK£41m |
| Mar 31 2023 | n/a | n/a | -UK£43m |
| Dec 31 2022 | UK£6m | UK£461k | -UK£40m |
| Sep 30 2022 | n/a | n/a | -UK£36m |
| Jun 30 2022 | n/a | n/a | -UK£39m |
| Mar 31 2022 | n/a | n/a | -UK£39m |
| Dec 31 2021 | UK£2m | UK£334k | -UK£39m |
Compensation vs Market: Craig's total compensation ($USD9.17M) is above average for companies of similar size in the US market ($USD3.40M).
Compensation vs Earnings: Craig's compensation has increased whilst the company is unprofitable.
CEO
Craig Tooman (58 yo)
2.3yrs
Tenure
UK£7,298,000
Compensation
Mr. Craig A. Tooman, MBA, serves as President, Chief Executive Officer and Executive Director of Silence Therapeutics plc since February 21, 2022. He has been a Supervisory Director of Curevac N. V. since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.3yrs | UK£7.30m | 0.024% £ 244.4k | |
| CFO & Secretary | 2.3yrs | UK£2.50m | 0.0011% £ 10.9k | |
| Head of Research & Development | 1.1yrs | UK£1.82m | 0.0093% £ 94.8k | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Head of IR & Corporate Communications | no data | no data | no data | |
| Senior VP and Chief Intellectual Property & Innovation Officer | 1.7yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 3.8yrs | no data | no data | |
| Chief Technical Operations Officer | 1.5yrs | no data | no data | |
| Chief Medical Officer | no data | no data | no data |
1.7yrs
Average Tenure
60yo
Average Age
Experienced Management: SLN's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.3yrs | UK£7.30m | 0.024% £ 244.4k | |
| Independent Non-Executive Director | 5.9yrs | UK£184.00k | 0.0054% £ 54.9k | |
| Chairman of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Independent Non-Executive Director | 3.3yrs | UK£178.00k | 0.0093% £ 94.8k | |
| Independent Chairman of the Board | 5.1yrs | UK£402.00k | 0.079% £ 802.5k | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Independent Non-Executive Director | 5.1yrs | UK£182.00k | 0.011% £ 109.4k | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.3yrs | no data | no data |
4.3yrs
Average Tenure
61yo
Average Age
Experienced Board: SLN's board of directors are considered experienced (4.3 years average tenure).